Naposomes: A new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications

Therapeutic Delivery

Volumn 2, Issue 2, 2011, Pages 235-257

  Accardo, Antonella ^a   Morisco, Anna ^a   Tesauro, Diego ^a   Pedone, Carlo ^a   Morelli, Giancarlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7-14 BOMBESIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BOMBESIN; CHELATING AGENT; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; GADOLINIUM DIETHYLENETRIAMINE PENTAACETIC ACID; GADOLINIUM PENTETATE; GADOTERIDOL; LIPOSOME; MONOMER; NANOPARTICLE; NAPOSOME; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OCTROSCAN; PACLITAXEL; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; POLYSORBATE 80; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BREAST CANCER; CARDIOTOXICITY; CELL PROLIFERATION; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG SAFETY; ENCAPSULATION; FLOW CYTOMETRY; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROPHOBICITY; LUNG METASTASIS; LYMPHOMA; MELANOMA; MICELLE; MOLECULAR WEIGHT; NERVOUS SYSTEM TUMOR; NEUROENDOCRINE TUMOR; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 79954479044     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.86     Document Type: Article

References (106)

1. Gregoriadis G, Ryman BE. Lysosomal localization of fructofuranoside- containing liposomes injected into rats. Biochem. J. 129, 123-133 (1972).
2. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271-84 (2000). (Pubitemid 30122932)
3. Bajoria R, Contractor SF. Effect of surface charge of small unilamellar liposomes on uptake and transfer of carboxyfluorescein across the perfused human term placenta. Pediatr. Res. 42, 520-527 (1997). (Pubitemid 27411161)
4. Miller CR, Bondurant B, McLean SD, McGovern KA, OBrien DF. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37, 12875-12883 (1998). (Pubitemid 28433520)
5. Nakanishi T, Kunisawa J, Hayashi A, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem. Biophys. Res.Commun. 240, 793-797 (1997). (Pubitemid 28271799)
6. Scherphof GL, Kamps JA. Receptor versus nonreceptor mediated clearance of liposomes. Adv. Drug Deliv. Rev. 32, 81-97 (1998). (Pubitemid 28277177)
7. Papisov MI. Theoretical considerations of RES-avoiding liposomes: molecular mechanics and chemistry of liposome interactions. Adv. Drug Deliv. Rev. 32, 119-138 (1998). (Pubitemid 28277179)
8. Bakker J, Sanders A, Van Rooijen N. Effects of liposome-encapsulated drugs on macrophages: comparative activity of the diamidine 4′,6- diamidino-2-phenylindole and the phenanthridinium salts ethidium bromide and propidium iodide. Biochim. Biophys. Acta 1373, 93-100 (1998). (Pubitemid 28495670)
9. Mayer LD. Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies. Cancer Metastasis Rev. 17, 211-218 (1998). (Pubitemid 28391956)
10. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154, 123-140 (1997). (Pubitemid 27351317)
11. Boswell GW, Buell D, Bekersky I. AmBisome® (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38, 583-592 (1998). (Pubitemid 28354895)
12. Allen TM. Liposomes: opportunities in drug delivery. Drugs 54, 8-14 (1997).
13. Allen TM, Moase EH. Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Deliv. Rev. 21, 117-133 (1996). (Pubitemid 26401714)
14. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta 1023, 133-139 (1990). (Pubitemid 20100771)
15. Bandak S, Ramu A, Barenholz Y, Gabizon A. Reduced UV-induced degradation of doxorubicin encapsulated in polyethylene glycol-coated liposomes. Pharm. Res. 16(6), 841-846 (1999). (Pubitemid 29284194)
16. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 53(3), 520-538 (1997). (Pubitemid 27117367)
17. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J. Control. Release 53, 275-279 (1998). (Pubitemid 28218710)
18. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19, 1444-1454 (2001). (Pubitemid 32202552)
19. Shiraga E, Barichello JM, Ishida T, Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int. J. Pharm. 353, 65-73 (2008).
20. Soepenberga O, Sparrebooma A, de Jongea JA, et al. Real-time pharmacokinetics guiding clinical decisions: Phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumors. Eur. J. Cancer 40, 681-688 (2004).
21. Mita M, Mita A, Sarantopoulos J, et al. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother. Pharmacol. 64(2), 287-295 (2009).
22. Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents Chemother. 42, 1412-1416 (1998). (Pubitemid 28257642)
23. Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB-lipid complex, and itraconazole. Antimicrob. Agents Chemother. 43, 1264-1266 (1999). (Pubitemid 29214759)
24. Jessup C, Reyes G, Fothergill A, et al. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study. J. Chemother. 12, 22-29 (2000). (Pubitemid 30139825)
25. Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33, 1544-1548 (1989). (Pubitemid 19228011)
26. Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5, 1854-1863 (2006). (Pubitemid 44323254)
27. Wang J, Goh B, Lu W, et al. In vitro cytotoxicity of stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 28, 822-828 (2005). (Pubitemid 40740648)
28. Battistini E, Gianolio E, Gref R, et al. High-relaxivity magnetic resonance imaging (MRI) contrast agent based on supramolecular assembly between a gadolinium chelate, a modified dextran, and poly-b -cyclodextrin. Chem. Eur. J. 14, 4551-4561 (2008).
29. Aime S, Botta M, Garino E, et al. Noncovalent conjugates between cationic polyamino acids and GdIII chelates: a route for seeking accumulation of MRI-contrast agents at tumor targeting sites. Chem. Eur. J. 6(14), 2609-2617 (2000).
30. Tilcock C, Unger E, Cullis P, MacDougall P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology 171(1), 77-80 (1989). (Pubitemid 19093047)
31. Kabalka G, Buonocore E, Hubner K, Moss T, Norley N, Huang L. Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology 163(1), 255-258 (1987). (Pubitemid 17043038)
32. Grant CWM, Karlik S, Florio EA. A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn. Reson. Med. 11(2), 236-243 (1989). (Pubitemid 19199037)
33. Unger E, Fritz T, Wu G, et al. Liposomal MR contrast agents. J. Liposome Res. 4(2), 811-834 (1994).
34. Unger E, Shen DK, Wu GL, Fritz T. Liposomes as MR contrast agents: pros and cons. Magn. Reson. Med. 22(2), 304-308 (1991).
35. Koenig SH, Ahkong QF, Brown RD III, et al. Permeability of liposomal membranes to water: results from the magnetic field dependence of T1 of solvent protons in suspensions of vesicles with entrapped paramagnetic ions. Magn. Reson. Med. 23(2), 275-286 (1992).
36. Kabalka GW, Davis MA, Buonocore E, Hubner K, Holmberg E, Huang L. Gadolinium-labeled liposomes containing amphipathic agents for magnetic resonance imaging. Invest. Radiol. 25(Suppl. 1), S63-S64 (1990). (Pubitemid 20276052)
37. Kabalka GW, Buonocore E, Hubner K, Davis M, Huang L. Gadolinium-labeled liposomes containing paramagnetic amphipathic agents: targeted MRI contrast agents for the liver. Magn. Reson. Med. 8(1), 89-95 (1988).
38. Kim SK, Pohost GM, Elgavish GA. Fatty-acyl iminopolycarboxylates: lipophilic bifunctional contrast agents for NMR imaging. Magn. Reson. Med. 22(1), 57-67 (1991).
39. Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today 9(5), 219-228 (2004). (Pubitemid 38230021)
40. Torchilin VP. Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Deliv. 5(9), 1003-1025 (2008).
41. Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin. Drug Deliv. 5(2), 189-204 (2008). (Pubitemid 351308311)
42. Wu H, Chang DK. Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J. Oncol. DOI: 10.1155/2010/723798 (2010). (Epub ahead of print).
43. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145-160 (2005). (Pubitemid 40282557)
44. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763. (2002). (Pubitemid 37328910)
45. van Tilborg GAF, Mulder WJM, Deckers N, et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem. 17(3), 741-749 (2006). (Pubitemid 43794385)
46. Mulder WJM, Strijkers GJ, van Tilborg GAF, Cormode DP, Fayad ZA, Nicolay K. nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc. Chem. Res. 42(7), 904-914 (2009).
47. Bull SR, Guler MO, Bras RE, Maede TJ, Stupp SI (Pubitemid 40168894)
48. Mulder WJM, Strijkers GJ, Griffioen AW, et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem. 15(4), 799-806 (2004). (Pubitemid 38981954)
49. Mulder WJM, Strijkers GJ, Briley-Saebo KC, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn. Reson. Med. 58(6), 1164-1170 (2007). (Pubitemid 350234203)
50. Lipinski MJ, Amirbekian V, Frias JC, et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson. Med. 56(3), 601-610 (2006). (Pubitemid 44338879)
51. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104(3), 961-966 (2007). (Pubitemid 46154719)
52. Li KCP, Bednarski MD. Vascular-targeted molecular imaging using functionalized polymerized vesicles. J. Magn. Res. Imaging 16(4), 388-393 (2002). (Pubitemid 35167874)
53. Storrs RW, Tropper FD, Li HY, et al. Paramagnetic polymerized liposomes: synthesis, characterization, and applications for magnetic resonance imaging. J. Am. Chem. Soc. 117(28), 7301-7306 (1995).
54. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KCP. Detection of tumor angiogenesis in vivo by avb3-targeted magnetic resonance imaging. Nat. Med. 4(5), 623-626 (1998). (Pubitemid 28237365)
55. Sipkins DA, Gijbels K, Tropper FD, Bednarski MD, Li KCP, Steinman L. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J. Neuroimmunol. 104(1), 1-9 (2000). (Pubitemid 30100884)
56. Bull SR, Guler MO, Bras RE, Venkatasubramanian PN, Stupp SI, Maede TJ. Magnetic resonance imaging of self-assembled biomaterial scaffolds. Bioconjug. Chem. 16(6), 1343-1348 (2005). (Pubitemid 41681497)
57. Mulder WJM, Strijkers GJ, Habets JW, et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 19(14), 2008-2010 (2005). (Pubitemid 41759747)
58. Mulder WJM, van der Schaft DWJ, Hautvast PAI, et al. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 21(2), 378-383 (2007).
59. Brandwijk RJ, Mulder WJ, Nicolay K, Mayo KH, Thijssen VL, Griffioen AW. Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug. Chem. 18(3), 785-790 (2007). (Pubitemid 47010798)
60. Kluza E, van der Schaft DW, Hautvast PA, et al. Synergistic targeting of avb3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 10(1), 52-58 (2010).
61. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5(3), 161-171 (2005). (Pubitemid 40314948)
62. Vaccaro M, Mangiapia G, Radulescu A, et al. Colloidal particles composed of amphiphilic molecules binding gadolinium complexes and peptides as tumor-specific contrast agents in MRI: physico-chemical characterization. Soft Matter 5(13), 2504-2512 (2009).
63. Accardo A, Tesauro D, Roscigno P, et al. Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI J. Am. Chem. Soc. 126, 3097-3107 (2004). (Pubitemid 38380714)
64. Mangiapia G, Accardo A, Lo Celso F, et al. Mixed micelles composed of peptides and gadolinium complexes as tumor-specific contrast agents in MRI: a SANS study. J. Phys. Chem. B 108, 17611-17617 (2004).
65. Vaccaro M, Accardo A, Tesauro D, et al. Supramolecular aggregates of amphiphilic gadolinium complexes as blood pool MRI/MRA contrast agents: physicochemical characterization. Langmuir 22(15), 6635-6643 (2006). (Pubitemid 44146899)
66. Accardo A, Tesauro D, Morelli G, et al. High-relaxivity supramolecular aggregates containing peptide and Gd complex agents in MRI. J. Biol. Inorg. Chem. 12, 267-276 (2007). (Pubitemid 46197950)
67. Tesauro D, Accardo A, Gianolio E, et al. Peptide derivatized lamellar aggregates as target-specific MRI contrast agents. ChemBioChem 8, 950-955 (2007). (Pubitemid 47194844)
68. Vaccaro M, Accardo A, D'Errico G, et al. Peptides and Gd complexes containing colloidal assemblies as tumor specific contrast agents in MRI: physicochemical characterization. Biophys. J. 93, 1736-1746 (2007). (Pubitemid 47403313)
69. Vaccaro M, Mangiapia G, Paduano L, et al. Structural and relaxometric characterization of peptide aggregates containing gadolinium complexes as potential selective contrast agents in MRI. ChemPhysChem 8, 2526-2538 (2007).
70. Accardo A, Tesauro D, Aloj L, et al. Peptide containing aggregates as selective nanocarriers for therapeutics. ChemMedChem 3, 594-602 (2008).
71. Accardo A, Tesauro D, Del Pozzo L, Mangiapia G, Paduano L, Morelli G. Micelles by self-assembling peptide-conjugate amphiphile: synthesis and structural characterization. J. Pept. Sci. 14, 903-910 (2008).
72. Vaccaro M, Mangiapia G, Accardo A, et al. Polymerized mixed aggregates containing gadolinium complex and CCK8 peptide. Colloid Polym. Sci. 286, 1643-1652 (2008).
73. Accardo A, Tesauro D, Morisco A, et al. Micelles obtained by aggregation of gemini surfactants containing the CCK8 peptide and a gadolinium complex. J. Biol. Inorg. Chem. 14, 587-599 (2009).
74. Morisco A, Accardo A, Tesauro D, Palumbo R, Benedetti E, Morelli G. Peptide labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells. Biopolymers DOI: 10.1002/bip.21491 (2010)(Epub ahead of print).
75. Accardo A, Mansi R, Morisco A, et al. Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol. Biosyst. 6, 878-887 (2010).
76. Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G. Micelles derivatized with octreotide as potential target selective contrast agents in MRI. J. Pept. Sci. 15, 242-250 (2009).
77. Accardo A, Morisco A, Gianolio E, et al. octreotide as target-selective delivery tool of nanoparticles for MRI application. J. Pept. Sci. DOI: 10.1002/psc.1308 (2010) (Epub ahead of print).
78. Silvente-Poirot S, Dufresne M, Vaysse N, Fourmy D. The peripheral cholecystokinin receptors. Eur. J. Biochem. 215, 513-529 (1993). (Pubitemid 23246820)
79. Wank SA. Cholecystokinin receptors. Am. J. Physiol. 269, G628-G646 (1995). (Pubitemid 3005920)
80. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 57(7), 1377-1386 (1997). (Pubitemid 27152565)
81. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol. Rev. 86(3), 805-847 (2006). (Pubitemid 44033383)
82. Pellegrini M, Mierke DF. Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy. Biochemistry 38, 14775-14783 (1999).
83. Aloj L, Caraco C, Panico M, et al. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J. Nucl. Med. 45(3), 485-494 (2004). (Pubitemid 47618625)
84. Battey JF, Way JM, Corjay MH, et al. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc. Natl Acad. Sci. USA 88(2), 395-399 (1991). (Pubitemid 21915471)
85. Fathi Z, Corjay MH, Shapira H, et al. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J. Biol. Chem. 268(8), 5979-5984 (1993). (Pubitemid 23090935)
86. Nagalla SR, Barry BJ, Creswick KC, Eden P, Taylor JT. Cloning of a receptor for amphibian [Phe-13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc. Natl Acad. Sci. USA 92(13), 6205-6209 (1995).
87. Wada E, Way J, Shapira H. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron 6(3), 421-430 (1991).
88. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 59(5), 1152-1159 (1999). (Pubitemid 29135980)
89. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 155(6), 2067-2076 (1999).
90. Fleischmann A, Waser B, Reubi JC. Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol. 29(5), 421-433 (2007). (Pubitemid 47255980)
91. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl. Med. Biol. 32(7), 733-740 (2005). (Pubitemid 41502979)
92. Lamberts SWJ. Somatostatin analogues from one decade to the second. In: octreotide: the Next Decade. Lamberts SWJ (Ed.). Bristol Bioscientifica, UK 3-65 (1999).
93. Bauer W, Briner U, Doepfner W. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31, 1133-1140 (1982). (Pubitemid 13243115)
94. Veber DF, Freidinger RM, Schwenk-Perlow D, et al. A potent cyclic hexapeptide analogue of somatostatin. Nature 292, 55-58 (1981). (Pubitemid 11048543)
95. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-d-Phe-(1)- Tyr- (3)-octreotide in comparison to [111In]- DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5, 42-48 (2003). (Pubitemid 36596544)
96. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28, 836-846; Erratum in: Eur. J. Nucl. Med. 28, 1433 (2001).
97. Bell G, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci. 16, 34-38 (1993).
98. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor host interaction? Int. J. Cancer 56, 681-688 (1994). (Pubitemid 24086771)
99. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 54, 3455-3459 (1994). (Pubitemid 24225966)
100. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24(4), 389-427 (2003). (Pubitemid 37056239)
101. Anelli PL, Lattuada L, Lorusso V, Schneider M, Tournier H, Uggeri F. Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. MAGMA 12(2-3), 114-120 (2001). (Pubitemid 32510129)
102. Accardo A, Tesauro D, Mangiapia G, Pedone C, Morelli G. Nanostructures by self-assembling peptide amphiphile as potential selective drug carriers. Biopolymers 88, 115-121 (2007). (Pubitemid 46657977)
103. Delli Castelli D, Gianolio E, Geninatti Crich S, Terreno E, Aime S. Metal containing nanosized systems for MR-molecular imaging applications. Coord. Chem. Rev. 252(21-22), 2424-2443 (2008).
104. Accardo A, Tesauro D, Aloj L, Pedone C, Morelli G. Supramolecular aggregates containing lipophilic Gd(III) complexes as contrast agents in MRI. Coord. Chem. Rev. 253(17-18), 2193-2213 (2009).
105. Menger FM, Littau CA. Gemini-surfactants: synthesis and properties. J. Am. Chem. Soc. 113, 1451-1452 (1991).
106. Zana R. Dimeric and oligomeric surfactants. Behavior at interfaces and in aqueous solution: a review. Adv Colloid Interface Sci. 97(1-3), 205-253 (2002). (Pubitemid 34292094)